Interview with Tapani Sura, General Manager, Astellas Poland
You were appointed general manager of Astellas Poland in early 2006, only a bit after Astellas Pharma Inc. was established, on April 1, 2005 through the merger of the mother…
Address: Osmanska 14 str.
02-823 Warsaw
Poland
Tel: +48 22 545 11 11
Over the past ten years, Astellas has built a strong position in Urology, Transplantation, and Antibiotics in the Polish market.
Therapy Areas
Transplantation
Urology
Dermatology
Gastroenterology
A Brief History
Astellas Pharma Sp. z o.o. was registered in August 2005 after the merger of the mother companies Yamanouchi and Fujisawa. Its predecessor, Yamanouchi Pharma Sp. z o.o., began its operation in 1999. Before that the business was handled through the Warsaw branch office of Yamanouchi, which was opened in 1992. Fujisawa Branch Office was opened in 2000.
Local Pharmaceutical Market Conditions
After a fast period of growth from 1991 to 2002, the Polish pharmaceutical market has become turbulent because of fast and sometimes unpredictable changes in reimbursement, pricing, and regulations. This has been the case especially when it comes to innovative pharma companies. As a matter of fact, apart from sartans, the last NCEs entered the reimbursement list in 1998. The policy of the Ministry of Health has been and still is to support local industry and generics producers. However, the size of the country (close to 40 million people) still makes it an attractive market.
Astellas Pharma Europe Ltd. is focused on five key therapeutic areas: Transplantation, Urology, Dermatology, Anti-infectives, and Pain Management. In addition, Astellas remains committed to improving the lives of patients with a number of other diseases, including Diabetes and Cardiovascular, CNS, Respiratory, and Gastrointestinal. As an organisation, Astellas is focused on and committed to its R&D programmes and is driven by its philosophy of enriching the lives of people around the world.
You were appointed general manager of Astellas Poland in early 2006, only a bit after Astellas Pharma Inc. was established, on April 1, 2005 through the merger of the mother…
“Innovation is about bringing new chemical compounds on the market; but it is also, and sometimes even more, to continue the therapeutic development of the drugs which are already there”…
Merck’s managing director discusses the importance of diversification to succeed in Poland by saying: “Nowadays, in such a dynamic environment the healthy level of diversification that Merck offers is becoming…
Medtronic’s country director brings some interesting perspectives on the differences between the pharma and medical device regulations in Poland by saying: “the medical device industry is discriminated against, as we…
The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the…
The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the…
The founder of PBA Consultancy offers a critical analysis of the new Reimbursement Act, looking at what could still be done to improve the system. Could you give us the…
Poland’s Main Pharmaceutical Inspector discusses the dangers behind falsified medicines and the need to control internet pharmacies. She also showcases the great power Poland holds as a manufacturing country with…
“In this very competitive environment, patents give companies an edge; this is why we must maintain innovative breakthroughs in our industry. This will then allow us to compete more efficiently…
“The overall Polish healthcare system is quite good. Of course, there are flaws, but Poland is equipped to treat almost any disease. The flaws in the system stem from historically…
In a world where diabetes increasingly more common, Poland has not been spared, with 2.5 million diabetic patients currently, and with a further 750,000 still unaware of their condition. In…
Cezary Sledziewski, Executive Director of PZPPF, discusses the pros and cons of Poland’s catching up with EU’s rising standards. He argues: “No one currently knows exactly how much these costs…
Polpharma , Poland’s role model and largest Polish manufacturer of drug products and active pharmaceutical ingredients, has pushed the Polish boundaries with the objective to become the fastest growing regional…
See our Cookie Privacy Policy Here